SUBSCRIBE
SUBSCRIBE
News   Drug Development

Achillion Pharmaceuticals, Inc. Provides Update on Clinical HCV Development Programs

November 12, 2012 | 
1 min read
NEW HAVEN, Conn., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today provided an update on the sovaprevir and ACH-3102 clinical development programs and announced new Phase 1b clinical trial results on ACH-2684.
Clinical research Phase I Phase II
MORE ON THIS TOPIC
Goal disorientation and lack of vision. Inability to set the right business objectives. Failure to achieve the objectives. Missing the unrealistic and inaccurate company goals.
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
July 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Wood block with healthcare medical icon on blue background. Health care insurance concept
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
July 15, 2025
 · 
4 min read
 · 
Tristan Manalac
Contemporary art collage. Conceptual design with young woman, motivated employee running forward to reach goal, professional success. Concept of business, career development, achievement
Obesity
Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III
July 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis